Unlocking the Power of PDX Mouse Clinical Trials in Oncology Drug Development
Scientist
on
October 22, 2024
This blog post was written by Crown Bioscience a global contract research organization (CRO) providing discovery, preclinical and translational platforms to advance oncology and immuno-oncology. Their services are available on the Scientist.com marketplace.
In the world of oncology drug development, the path to clinical success is fraught with challenges. With a failure rate of nearly 75% for oncology drugs in Phase II clinical trials, the need for more predictive preclinical models is urgent. While traditional models have played a significant role in drug discovery, they often fall short when it comes to translating results from the lab to the clinic. One solution gaining prominence is the use of patient-derived xenograft (PDX) models, a more reliable and clinically relevant tool that mimics human tumor biology in mice, offering a closer approximation of how a drug will perform in real patients.
Traditional Models: A Legacy of Limitations
For many years, cell line-derived tumor models have been the standard in preclinical oncology research. These models are grown in a 2D structure in vitro and then implanted into mice for drug testing. While they are useful in early drug discovery for testing pharmacokinetics and pharmacodynamics, these models suffer from reduced clinical relevance. The process of culturing tumor cells on plastic can alter their genetic makeup, making them less representative of actual human tumors.
PDX Models: A Translational Leap Forward
Patient-derived xenograft (PDX) models solve many of the limitations seen in traditional cell line models. PDX models are created by directly implanting human tumor tissue into immunocompromised mice, preserving the genetic integrity and heterogeneity of the original patient tumor. This approach provides a much closer reflection of how a human tumor behaves in vivo, making PDX models highly translational.
PDX models are characterized at a deep molecular level, including gene expression, gene copy number, mutations and responses to standard-of-care therapies. Because they maintain the complex tumor microenvironment and heterogeneity seen in patients, PDX models offer a more accurate representation of drug response and resistance patterns. For oncology researchers, this means better predictability of clinical outcomes.
Mouse Clinical Trials (MCTs): A More Predictive Approach
One of the most powerful applications of PDX models is mouse clinical trials (MCTs). Traditional preclinical trials test a small number of models with large groups of subjects, but this method doesn’t accurately reflect patient diversity. MCTs flip this paradigm, testing a large number of PDX models, each representing a unique patient, with small subject groups. This allows researchers to mimic the complexity of human clinical trials, with each PDX model acting as a “patient avatar.”
MCTs provide researchers with predictive data on drug responses in various subgroups, identifying potential responders and non-responders before moving to human trials. This approach enables better stratification of patient populations, offering insights into which groups are most likely to benefit from a treatment and which might experience resistance.
Click here to access the white paper
Biomarker Discovery and Precision Medicine
One of the greatest strengths of PDX models and MCTs lies in their potential for biomarker discovery. Biomarkers — molecular signals that indicate a patient’s likely response to a drug — are critical for the development of personalized therapies. With PDX models, researchers can gather rich data that mirrors the genetic and proteomic landscape of actual patient populations. By comparing drug responses between responder and non-responder groups, MCTs facilitate the identification of genomic or proteomic differences that can serve as biomarkers for patient stratification.
For instance, by analyzing the gene expression profiles of treated PDX models, researchers can uncover mutations or protein expression patterns that correlate with drug efficacy. This information can be used to guide clinical trial design, ensuring that the right patients are selected for the right therapies, significantly improving the chances of clinical success.
Enhancing Clinical Success Rates
The impact of biomarkers on clinical trial success rates is profound. Trials that incorporate biomarkers tend to have a much higher likelihood of success, especially in the critical Phase II to Phase III transition. This is because biomarkers help identify patient subgroups that are more likely to respond to the treatment, reducing variability and improving the precision of the trial.
Why PDX Mouse Clinical Trials Matter for Oncology Drug Development
At the end of the day, the goal of oncology drug development is to bring more effective treatments to patients faster. PDX mouse clinical trials are helping researchers achieve this goal by providing highly predictive data in a preclinical setting. They enable better-informed decision-making, help reduce the high attrition rates of oncology drugs and offer powerful tools for biomarker discovery and patient stratification.
Crown Bioscience, with its vast biobank of over 2,600 PDX models covering more than 30 cancer types, is at the forefront of advancing PDX research. With extensive experience in executing and analyzing MCTs, Crown offers a comprehensive platform that supports oncology drug discovery from preclinical stages to clinical translation.
Learn More About Mouse Clinical Trials
Conclusion
By leveraging PDX models in mouse clinical trials, researchers can dramatically improve the predictability of clinical outcomes, identify actionable biomarkers and better stratify patient populations. As the oncology field continues to move towards personalized medicine, PDX mouse clinical trials will play a pivotal role in ensuring that the right drugs reach the right patients at the right time.